Pfizer Inc. CEO Albert Bourla has vowed that his company will maintain high scientific standards in developing its COVID-19 vaccine and will not be pressured into filing if there are not sufficient data from its ongoing Phase III trial.
He also repeated his forecast that the data could be ready by October, which could allow for it to gain...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
